Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,049
  • Shares Outstanding, K 40,032
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,040 K
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78
Trade CNSP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings -0.07 on 05/16/22
  • Next Earnings Date 05/13/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +666,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2610 +5.75%
on 05/12/22
0.3980 -30.65%
on 04/29/22
-0.0707 (-20.39%)
since 04/20/22
3-Month
0.2453 +12.52%
on 03/08/22
0.5500 -49.82%
on 03/01/22
-0.0612 (-18.15%)
since 02/18/22
52-Week
0.2453 +12.52%
on 03/08/22
2.6800 -89.70%
on 06/29/21
-1.6140 (-85.40%)
since 05/20/21

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at American Society of Clinical Oncology Meeting

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released...

CNSP : 0.2760 (-4.83%)
Investor Event Puts Spotlight on Brain Cancer Drug Trial by CNS Pharmaceuticals (NASDAQ: CNSP)

Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”)...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals’ (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) Focused on Advancing Research on GBM Treatments

CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers....

CNSP : 0.2760 (-4.83%)
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and...

AEZS : 0.1986 (-2.17%)
CNSP : 0.2760 (-4.83%)
AREC : 1.5200 (-0.65%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights at Virtual Growth Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently...

CNSP : 0.2760 (-4.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at 2022 Virtual Growth Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”),...

CNSP : 0.2760 (-4.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.3216
2nd Resistance Point 0.3108
1st Resistance Point 0.2934
Last Price 0.2760
1st Support Level 0.2652
2nd Support Level 0.2544
3rd Support Level 0.2370

See More

52-Week High 2.6800
Fibonacci 61.8% 1.7499
Fibonacci 50% 1.4627
Fibonacci 38.2% 1.1754
Last Price 0.2760
52-Week Low 0.2453

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar